ScreenerHero

ELDNEledon Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · eledon.com
3.450USD-2.82%Mkt Cap: 280.35M $P/E: —

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and preve…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap280.35M $
Enterprise Value197.75M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.62M $
Revenue/Share—
Last Price3.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS28617K1016
Valuation
P/E (Trailing)—
P/E (Forward)-4.57
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.66
EPS (TTM)-0.90
EPS (Forward)-0.77
52W Range
1.35065% of range4.600
52W High4.600 USD
52W Low1.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.26%
ROA-26.99%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.34M $
CapEx (TTM)—
FCF Margin—
FCF Yield-16.09%
Net Debt-88.29M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio7.90
Quick Ratio7.57
Book Value/Sh1.322 USD
Cash/Share1.092 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 5, 2020
Splits
Last Split1:18
Split DateOct 5, 2020
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+160.9%
Target Range7.000 USD – 12.00 USD
$7.000+160.9% to mean$12.00
# Analysts5
Ownership
Shares Out.81.26M
Float74.60M
Insiders0.33%
Institutions62.46%
Short Interest
Short Ratio5.2d
Short % Float8.05%
Short % Out.8.05%
Shares Short6.21M
Short (prev mo.)7.83M
Technical
SMA 503.720 (-7.3%)
SMA 2002.902 (+18.9%)
Beta0.96
S&P 52W Chg18.16%
Avg Vol (30d)979.14K
Avg Vol (10d)860.37K
Technical Indicators
RSI (14)42.1
MACD-0.0437
MACD Signal-0.0446
MACD Hist.+0.0009
BB Upper3.822 USD
BB Middle3.546 USD
BB Lower3.270 USD
BB Width15.58%
ATR (14)0.2003 USD
Vol Ratio (20d)0.75x